secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001213900-25-018334
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BBOT to merge with Helix II SPAC in $450M deal; public listing expected Q3 2025
-------------------------------------------------------------------------------

- Total proceeds ~$450M from Helix trust (~$196M) and $260M PIPE led by Cormorant, including Deerfield, Novo Holdings, Wellington.
- Combined company to be named BridgeBio Oncology Therapeutics (BBOT), trading on Nasdaq under ticker BBOT.
- Pro forma equity value ~$949M at $10.36/share assuming no redemptions; BBOT shareholders roll 100% equity.
- Lead programs: BBO-8520 (KRAS G12C Phase 1), BBO-10203 (RAS-PI3Kα Phase 1), BBO-11818 (pan-KRAS Phase 1 starting H1 2025).
- Transaction approved by both boards; expected close Q3 2025, subject to stockholder approvals and conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025018334/0001213900-25-018334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390025018334/ea0232555-8k425_helix2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-018334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer